Point72 Asset Management L.P. trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 47.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 119,964 shares of the medical device company’s stock after selling 107,546 shares during the quarter. Point72 Asset Management L.P.’s holdings in DexCom were worth $26,241,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of DXCM. Candriam Luxembourg S.C.A. boosted its holdings in DexCom by 14.7% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 6,758 shares of the medical device company’s stock valued at $1,478,000 after acquiring an additional 868 shares during the last quarter. Franklin Resources Inc. increased its position in shares of DexCom by 12.0% during the fourth quarter. Franklin Resources Inc. now owns 302,001 shares of the medical device company’s stock valued at $66,059,000 after acquiring an additional 32,377 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of DexCom during the third quarter valued at approximately $222,000. Beck Bode LLC purchased a new stake in shares of DexCom during the third quarter valued at approximately $1,571,000. Finally, MAI Capital Management purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $202,000. 98.47% of the stock is owned by institutional investors.

DXCM has been the subject of a number of research analyst reports. Stephens decreased their price target on DexCom from $300.00 to $240.00 and set an “overweight” rating for the company in a research report on Monday. JPMorgan Chase & Co. boosted their target price on shares of DexCom from $215.00 to $255.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. BidaskClub lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 18th. Bank of America reiterated a “buy” rating and set a $250.00 target price (up from $220.00) on shares of DexCom in a research note on Wednesday, December 18th. Finally, Piper Sandler boosted their target price on shares of DexCom from to in a research note on Friday, February 14th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $259.95.

Shares of DXCM traded up $3.12 during midday trading on Wednesday, hitting $239.33. 1,046,024 shares of the company traded hands, compared to its average volume of 1,126,464. The firm has a 50 day moving average of $258.83 and a 200-day moving average of $209.84. DexCom, Inc. has a 52 week low of $107.44 and a 52 week high of $306.71. The stock has a market cap of $22.06 billion, a price-to-earnings ratio of 221.60, a PEG ratio of 2.55 and a beta of 0.61. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.13 and a current ratio of 5.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.74 by $0.41. DexCom had a net margin of 6.85% and a return on equity of 22.65%. The business had revenue of $462.80 million during the quarter, compared to the consensus estimate of $457.00 million. Sell-side analysts predict that DexCom, Inc. will post 2.25 earnings per share for the current fiscal year.

In other DexCom news, SVP Patrick Michael Murphy sold 500 shares of DexCom stock in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $235.01, for a total transaction of $117,505.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Steven R. Altman sold 2,500 shares of DexCom stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $218.33, for a total transaction of $545,825.00. Following the transaction, the director now directly owns 2,676 shares in the company, valued at $584,251.08. The disclosure for this sale can be found here. Insiders have sold a total of 96,226 shares of company stock valued at $25,292,532 in the last three months. Insiders own 0.88% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: Equal Weight Rating

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.